Clinical Trial
doi: 10.1016/s0924-9338(02)00003-2.The clinical use of milnacipran for depression
Affiliations
- PMID:12648895
- DOI: 10.1016/s0924-9338(02)00003-2
Item in Clipboard
Clinical Trial
The clinical use of milnacipran for depression
Shigeru Morishita et al. Eur Psychiatry.2003 Feb.
Display options
Format
Display options
Format
Abstract
We examined the relation between dosage and efficacy, and the predictors of response to milnacipran. There was no difference between 50 and 100 mg dose. However, the 100 mg dose had a faster onset of action than the 50 mg dose. An age and an episode have been predictors of milnacipran.
Similar articles
- Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.Morishita S, Arita S.Morishita S, et al.Hum Psychopharmacol. 2003 Aug;18(6):479-82. doi: 10.1002/hup.508.Hum Psychopharmacol. 2003.PMID:12923828
- Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients.Sugawara Y, Higuchi H, Yoshida K, Takahashi H, Kamata M, Naito S, Sato K, Shimizu T.Sugawara Y, et al.Clin Neuropharmacol. 2006 Jan-Feb;29(1):6-9. doi: 10.1097/00002826-200601000-00003.Clin Neuropharmacol. 2006.PMID:16518126
- Controlled comparison of two different doses of milnacipran in major depressive outpatients.Kanemoto K, Matsubara M, Yamashita K, Tarao Y, Inada E, Sekine T.Kanemoto K, et al.Int Clin Psychopharmacol. 2004 Nov;19(6):343-6. doi: 10.1097/00004850-200411000-00005.Int Clin Psychopharmacol. 2004.PMID:15486520Clinical Trial.
- Reboxetine: a norepinephrine selective reuptake pump inhibitor.Preskorn SH.Preskorn SH.J Psychiatr Pract. 2004 Jan;10(1):57-63. doi: 10.1097/00131746-200401000-00006.J Psychiatr Pract. 2004.PMID:15334987Review.No abstract available.
- Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.Pennybaker SJ, Niciu MJ, Luckenbaugh DA, Zarate CA.Pennybaker SJ, et al.J Affect Disord. 2017 Jan 15;208:560-566. doi: 10.1016/j.jad.2016.10.026. Epub 2016 Oct 26.J Affect Disord. 2017.PMID:27839782Free PMC article.Review.
Cited by
- Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan.Higuchi T, Briley M.Higuchi T, et al.Neuropsychiatr Dis Treat. 2007 Feb;3(1):41-58. doi: 10.2147/nedt.2007.3.1.41.Neuropsychiatr Dis Treat. 2007.PMID:19300537Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical